But when is it legally acceptable not to tell the DVLA about it - and at what point should you let them know you have one? The DVLA, also known as the Driver and Vehicle Licensing Agency, manage ...
Notifiable conditions are medical issues that could affect your ability to drive safely. These can include sleep apnoea, ...
AUSTIN, Texas--(BUSINESS WIRE)--IntraBio Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for levacetylleucine for the ...
OBJECTIVES: To assess balance and ability to function in patients with spinocerebellar ataxia. METHODS: A total of 44 patients with different spinocerebellar ataxia types 1, 2, 3, and 6 were evaluated ...
Levacetylleucine significantly improves neurological symptoms and functioning in patients with ataxia-telangiectasia, according to results from the IB1001-303 clinical trial. Topline results were ...
In the CRL, the Agency concluded that the NDA could not be accepted due to issues that are inherent to real-world evidence and external control studies. The Food and Drug Administration (FDA) has ...
Please provide your email address to receive an email when new articles are posted on . Approximately 5,000 people in the United States have Friedreich’s ataxia. Advocates virtually met with ...
Home-based high-intensity aerobic training was associated with greater improvement in cerebellar ataxia symptoms, fitness, and fatigue compared with guidelines-recommended balance training in a ...
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...
An IgE deficiency was demonstrated in 11 of 16 patients with ataxia-telangiectasia. No relation to age or to the level of IgG, IgM or IgD was found. Nine out of 11 patients with IgE and IgA deficiency ...
Omaveloxolone, also known as RTA 408, is a semisynthetic triterpenoid originally developed from oleanolic acid derivatives and engineered to enhance intrinsic antioxidant defenses. This compound ...
Query: Characterization of cellular models for Friedreich’s ataxia including patient fibroblasts, iPSC-derived cell types, shRNA/CRISPR-mediated FXN knockdown lines, and identification of robust ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results